JSL Publishes Q3 2026 Results Presentation
Bitget2026/10/30 14:42- JSL’s third-quarter 2026 presentation outlined R$ 1.8 billion in business, adding R$ 38 million in monthly gross revenue.
- Another R$ 675 million in business contributed R$ 28 million in additional monthly gross revenue.
- A further R$ 319 million in business added R$ 8 million in monthly gross revenue.
- Average terms for the three business portfolios were 48 months, 24 months and 42 months, respectively.
- Cross-selling accounted for 100% of the largest and smallest portfolios; the remaining portfolio comprised 97% cross-selling and 3% new clients.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
